Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity

Contraception

Volumn 80, Issue 2, 2009, Pages 119-127

  Edelman, Alison B ^a   Carlson, Nichole E ^b   Cherala, Ganesh ^c   Munar, Myrna Y ^c   Stouffer, Richard L ^a,d   Cameron, Judy L ^a,d   Stanczyk, Frank Z ^e   Jensen, Jeffrey T ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c OREGON STATE UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BMI; Contraception failure; Obesity; Oral contraception; Unplanned pregnancy

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FOLLITROPIN; INHIBIN B; LEVONORGESTREL; LUTEINIZING HORMONE; PROGESTERONE; SEX HORMONE BINDING GLOBULIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG WITHDRAWAL; FEMALE; HORMONAL CONTRACEPTION; HOSPITAL ADMISSION; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NEGATIVE FEEDBACK; OBESITY; ORAL CONTRACEPTION; OVARY FOLLICLE DEVELOPMENT; OVARY FUNCTION; OVULATION; PATIENT COMPLIANCE; PROSPECTIVE STUDY; PULSATILE HORMONE RELEASE; SEX HORMONE DETERMINATION; STEADY STATE; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, COMBINED; ESTRADIOL; ETHINYL ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; LEVONORGESTREL; LUTEINIZING HORMONE; OBESITY; YOUNG ADULT;

EID: 67651005121     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.contraception.2009.04.011     Document Type: Article

References (21)

1. Finer L.B., and Henshaw S.K. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health 38 (2006) 90-96
2. Holt V.L., Cushing-Haugen K.L., and Darling J.R. Body weight and risk of oral contraceptive failure. Obstet Gynecol 99 (2002) 820-827
3. Hol V.L., Scholes D., Wickland K.G., Cushing-Haugen K.L., and Darling J.R. Body mass index, weight, and oral contraceptive failure risk. Obstet Gynecol 105 (2005) 46-52
4. Brunner L.R., and Hogue C.J. The role of body weight in oral contraceptive failure: results from the 1995 National Survey of Family Growth. Ann Epidemiol 15 (2005) 492-499
5. Brunner Huber L.R., and Toth J.L. Obesity and oral contraceptive failure: findings from the 2002 National Survey of Family Growth. Am J Epidemiol 166 (2007) 1306-1311
6. Kaneshiro B., Edelman A., Carlson N., Nichols M., and Jensen J.T. The relationship between body mass index and unintended pregnancy results from the 2002 National Survey of Family Growth. Contraception 77 (2008) 234-238
7. Blouin R.A., and Warren G.W. Pharmacokinetic considerations in obesity. J Pharm Sci 88 (1999) 1-7
8. Speroff L., Glass R.H., and Kase N.G. Clinical gynecologic endocrinology and infertility. 6th ed. (1999), Lippincott Williams & Wilkins, Baltimore (MD)
9. Price T.M., Dupuis R.E., Carr B.R., Stanczyk F.Z., Lobo R.A., and Droegemueller W. Single and multiple dose pharmacokinetics of a low dose oral contraceptive in women with chronic renal failure undergoing peritoneal dialysis. Am J Obstet Gynecol 168 (1993) 1400-1406
10. Stanczyk F.Z., Hiroi M., Goebelsmann U., Brenner P.F., Lumkin M.E., and Mishell Jr. D.R. Radioimmunoassay of serum d-Norgestrel in women following oral and intravaginal administration. Contraception 12 (1975) 279
11. Rowland M., and Tozer T.N. Clinical pharmacokinetics: concepts and applications (1980), Lea & Febiger, Philadelphia (Pa)
12. Veldhuis J.D., and Johnson M.L. Deconvolution analysis of hormone data. Methods Enzymol 210 (1992) 539-575
13. Fotherby K. Pharmacokinetics of gestagens: some problems. Am J Obstet Gynecol 163 (1990) 323-328
14. Irizar A., Barnett C.R., Flatt P.R., and Ioannides C. Defective expression of cytochrome P450 proteins in the liver of the genetically obese Zucker rat. Eur J Pharmacol 293 (1995) 385-393
15. Yoshinari K., Takagi S., Yoshimasa T., Sugatani J., and Miwa M. Hepatic CYP3A expression is attenuated in obese mice fed a high-fat diet. Pharm Res 23 (2006) 1188-1200
16. Fotherby K. Levonorgestrel. Clinical pharmacokinetics. Clin Pharmacokinet 28 (1995) 203-215
17. Sambol N.C., Harper C.C., Kim L., Liu C.Y., Darney P., and Raine T.R. Pharmacokinetics of single-dose levonorgestrel in adolescents. Contraception 74 (2006) 104-109
18. Wang B., Sanchez R.I., Franklin R.B., Evans D.C., and Huskey S.E. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 32 (2004) 1209-1212
19. Goldzieher J., and Stanczyk F.Z. Oral contraceptives and individual variability of circulating levels of ethinyl estradiol and progestins. Contraception 78 (2008) 4-9
20. van Heusden A.M., and Fauser B.C.J.M. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception 59 (1999) 237-243
21. Cohen B.L., and Katz M. Pituitary and ovarian function in women receiving hormonal contraception. Contraception 20 (1979) 475-487